Deutsche Raises Price Target on Alexion Pharm (ALXN), Encouraged About R&D Ramp Up

Deutsche Bank is reaffirming its Buy rating on shares of Alexion Pharmaceuticals (NASDAQ: ALXN), while boosting its price target from $78 to $92.

The company reported solid Q4 results and offered FY12 guidance which indicates the company is over doubling its R&D expenses. Some of ALXN's key investment for the year will include, asfotase alfa for hypophosphatasia, ph 3 trials of Soliris in kidney transplant and Soliris proof of concept trials in NMO & MG.

An analyst at Deutsche comments, "We see fruits of investment beginning to emerge in late 2013/2014 with launch of Soliris in STEC HUS & kidney transplant & asfotase alfa for hypophosphatasia"

The firm lowered its FY12 EPS estimate from $1.76 to $1.70 on 1.05 billion in total sales.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $80.41 yesterday, with a 52 week range of $43.78-$105.00.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1
• UBS Lowers Estimates and PT on Lowe's (LOW) Messy Q1, But Bullish Case Remains
• Barclays Cuts Estimates on Lowe's (LOW); Gross Margins Under Pressure; Performance Lags HD

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Deutsche Bank

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter